Table 4.
The treatment of patients who are progressing and those who are stable [39]
| Total (N = 1337) | Mild‑moderate (N = 1000) | Severe‑critical (N = 337) | P value | |
|---|---|---|---|---|
| Treatment | 1337 | 1000 | 337 | |
| Antiviral therapy | ||||
| Antibiotic therapy | 109 (8.15%) | 61 (4.56%) | 58 (4.33%) | < 0.002 |
| Use of corticosteroid | 99 (7.40%) | 32 (2.39%) | 78 (5.83%) | < 0.002 |
| Use of gamma globulin | 91 (6.80%) | 28 (2.09%) | 73 (5.54%) | < 0.002 |
| Regulate intestinal flora | 189 (14.13%) | 133 (9.94%) | 66 (4.93%) | < 0.002 |
| Oxygen support | 248 (18.54%) | 170 (12.71%) | 89 (6.65%) | |
| Nasal cannula | 191 (14.28%) | 167 (12.49%) | 33 (2.46%) | < 0.002 |
| Mask oxygen inhalation | 9 (0.67%) | 5 (0.37%) | 4 (0.29%) | 0.047 |
| High-flow nasal cannula | 12 (0.89%) | 0 | 10 (0.74%) | |
| Non-invasive ventilation | 26 (1.94%) | 0 | 28 (2.09%) | |
| Invasive mechanical ventilation | 13 (0.97%) | 0 | 16 (1.19%) | |
| Invasive mechanical ventilation + ECOM | 7 (0.52%) | 0 | 7 (0.52%) | |
| IL-6 (pg/mL) | 10(0.74%) | 4(0.4%) | 6(1.7%) | < 0.001 |
| Acute respiratory distress syndrome | 16 (1.19%) | 0 | 16 (1.19%) | |